nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0231	0.027	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0221	0.0259	CbGpPWpGaD
Solifenacin—CHRM4—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0197	0.0231	CbGpPWpGaD
Solifenacin—CHRM4—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0191	0.0224	CbGpPWpGaD
Solifenacin—CHRM5—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0189	0.0221	CbGpPWpGaD
Solifenacin—CHRM5—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0183	0.0214	CbGpPWpGaD
Solifenacin—CHRM4—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0178	0.0208	CbGpPWpGaD
Solifenacin—CHRM5—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0171	0.02	CbGpPWpGaD
Solifenacin—CHRM4—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0166	0.0194	CbGpPWpGaD
Solifenacin—CHRM4—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0161	0.0188	CbGpPWpGaD
Solifenacin—CHRM5—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0159	0.0186	CbGpPWpGaD
Solifenacin—CHRM4—nervous system—Gilles de la Tourette syndrome	0.0156	0.107	CbGeAlD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0156	0.0182	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0155	0.0182	CbGpPWpGaD
Solifenacin—CHRM5—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0154	0.018	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0154	0.018	CbGpPWpGaD
Solifenacin—CHRM4—central nervous system—Gilles de la Tourette syndrome	0.015	0.103	CbGeAlD
Solifenacin—CHRM4—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.015	0.0175	CbGpPWpGaD
Solifenacin—CHRM5—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0143	0.0168	CbGpPWpGaD
Solifenacin—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0133	0.0155	CbGpPWpGaD
Solifenacin—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0132	0.0155	CbGpPWpGaD
Solifenacin—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0131	0.0153	CbGpPWpGaD
Solifenacin—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0129	0.0151	CbGpPWpGaD
Solifenacin—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0129	0.015	CbGpPWpGaD
Solifenacin—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0127	0.0149	CbGpPWpGaD
Solifenacin—CHRM4—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0125	0.0146	CbGpPWpGaD
Solifenacin—CHRM5—nervous system—Gilles de la Tourette syndrome	0.0122	0.0839	CbGeAlD
Solifenacin—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.012	0.0141	CbGpPWpGaD
Solifenacin—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.012	0.014	CbGpPWpGaD
Solifenacin—CHRM5—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0119	0.014	CbGpPWpGaD
Solifenacin—CHRM4—brain—Gilles de la Tourette syndrome	0.0119	0.082	CbGeAlD
Solifenacin—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0119	0.0139	CbGpPWpGaD
Solifenacin—CHRM5—central nervous system—Gilles de la Tourette syndrome	0.0118	0.0808	CbGeAlD
Solifenacin—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0112	0.0131	CbGpPWpGaD
Solifenacin—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0111	0.013	CbGpPWpGaD
Solifenacin—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.011	0.0129	CbGpPWpGaD
Solifenacin—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0108	0.0127	CbGpPWpGaD
Solifenacin—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0108	0.0126	CbGpPWpGaD
Solifenacin—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0107	0.0125	CbGpPWpGaD
Solifenacin—CHRM4—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0105	0.0123	CbGpPWpGaD
Solifenacin—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0101	0.0118	CbGpPWpGaD
Solifenacin—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0101	0.0118	CbGpPWpGaD
Solifenacin—CHRM5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.01	0.0118	CbGpPWpGaD
Solifenacin—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00997	0.0117	CbGpPWpGaD
Solifenacin—CHRM5—brain—Gilles de la Tourette syndrome	0.00933	0.0641	CbGeAlD
Solifenacin—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00841	0.00985	CbGpPWpGaD
Solifenacin—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00839	0.00981	CbGpPWpGaD
Solifenacin—CHRM2—nervous system—Gilles de la Tourette syndrome	0.00838	0.0576	CbGeAlD
Solifenacin—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0083	0.00972	CbGpPWpGaD
Solifenacin—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.00807	0.0554	CbGeAlD
Solifenacin—CHRM1—nervous system—Gilles de la Tourette syndrome	0.00763	0.0524	CbGeAlD
Solifenacin—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.00735	0.0505	CbGeAlD
Solifenacin—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00707	0.00828	CbGpPWpGaD
Solifenacin—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00705	0.00825	CbGpPWpGaD
Solifenacin—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00698	0.00817	CbGpPWpGaD
Solifenacin—CHRM3—nervous system—Gilles de la Tourette syndrome	0.00683	0.0469	CbGeAlD
Solifenacin—CHRM3—central nervous system—Gilles de la Tourette syndrome	0.00657	0.0452	CbGeAlD
Solifenacin—CHRM2—brain—Gilles de la Tourette syndrome	0.00641	0.044	CbGeAlD
Solifenacin—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00588	0.00688	CbGpPWpGaD
Solifenacin—CHRM1—brain—Gilles de la Tourette syndrome	0.00583	0.0401	CbGeAlD
Solifenacin—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00582	0.00682	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00571	0.00668	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00565	0.00662	CbGpPWpGaD
Solifenacin—CHRM3—brain—Gilles de la Tourette syndrome	0.00522	0.0359	CbGeAlD
Solifenacin—CHRM4—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.0041	0.00479	CbGpPWpGaD
Solifenacin—CHRM4—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00398	0.00465	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0038	0.00445	CbGpPWpGaD
Solifenacin—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00375	0.0258	CbGeAlD
Solifenacin—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00372	0.00436	CbGpPWpGaD
Solifenacin—CHRM4—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.0037	0.00434	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00369	0.00432	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00369	0.00432	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00364	0.00426	CbGpPWpGaD
Solifenacin—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00361	0.0248	CbGeAlD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00353	0.00414	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00344	0.00402	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00329	0.00385	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00326	0.00381	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00316	0.0037	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00313	0.00366	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00312	0.00365	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00304	0.00356	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00303	0.00354	CbGpPWpGaD
Solifenacin—CHRM5—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00298	0.00349	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00295	0.00345	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00283	0.00331	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00282	0.0033	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00273	0.00319	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00267	0.00312	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00265	0.0031	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00256	0.003	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00255	0.00299	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00253	0.00296	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00249	0.00291	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00248	0.0029	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00248	0.0029	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00247	0.00289	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00246	0.00287	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00241	0.00282	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00241	0.00282	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.0024	0.0028	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00237	0.00278	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00232	0.00271	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00231	0.0027	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00231	0.0027	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00231	0.0027	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00229	0.00268	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00224	0.00262	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.0022	0.00257	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00219	0.00256	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00217	0.00254	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00215	0.00251	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00213	0.00249	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00213	0.00249	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0021	0.00246	CbGpPWpGaD
Solifenacin—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.0021	0.00246	CbGpPWpGaD
Solifenacin—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00209	0.00245	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00206	0.00241	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00199	0.00232	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00198	0.00232	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00198	0.00231	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00196	0.00229	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00188	0.0022	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00187	0.00219	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00167	0.00196	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00167	0.00195	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00165	0.00193	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00162	0.0019	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00162	0.0019	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00162	0.00189	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00162	0.00189	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0016	0.00188	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0016	0.00188	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.0016	0.00187	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00157	0.00184	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00151	0.00177	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00151	0.00176	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0015	0.00176	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00149	0.00175	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.0014	0.00164	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00139	0.00163	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00139	0.00162	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00137	0.00161	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00136	0.00159	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00134	0.00157	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.0013	0.00152	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00127	0.00149	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00127	0.00148	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00124	0.00145	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00122	0.00143	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00121	0.00142	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00118	0.00138	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00115	0.00135	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.0011	0.00129	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00106	0.00124	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00106	0.00124	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00105	0.00122	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000945	0.00111	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000942	0.0011	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000933	0.00109	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000917	0.00107	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000914	0.00107	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000906	0.00106	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000888	0.00104	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000858	0.001	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000855	0.001	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000855	0.001	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000852	0.000997	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00085	0.000995	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000847	0.000991	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000844	0.000987	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000833	0.000975	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00083	0.000972	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000822	0.000962	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000806	0.000943	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000776	0.000908	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000774	0.000905	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000772	0.000903	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000766	0.000897	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000752	0.00088	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00073	0.000854	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00072	0.000843	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000699	0.000818	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00068	0.000796	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000651	0.000762	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.000625	0.000731	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000599	0.000701	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000597	0.000698	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000591	0.000692	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000544	0.000636	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000542	0.000634	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000537	0.000628	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000507	0.000593	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000505	0.000591	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.0005	0.000586	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000492	0.000576	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000491	0.000574	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000486	0.000569	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000476	0.000557	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000458	0.000537	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000457	0.000535	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000456	0.000534	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000453	0.00053	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000321	0.000376	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00032	0.000375	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000317	0.000371	CbGpPWpGaD
